Authors:
Schumacher, S
Abbasi, I
Weise, D
Hatorp, V
Sattler, K
Sieber, J
Hasslacher, C
Citation: S. Schumacher et al., Single- and multiple-dose pharmacokinetics of repaglinide in patients withtype 2 diabetes and renal impairment, EUR J CL PH, 57(2), 2001, pp. 147-152
Citation: V. Hatorp et Ms. Thomsen, Drug interaction studies with repaglinide: Repaglinide on digoxin or theophylline pharmacokinetics and cimetidine on repaglinide pharmacokinetics, J CLIN PHAR, 40(2), 2000, pp. 184-192
Authors:
Damsbo, P
Marbury, TC
Hatorp, V
Clauson, P
Muller, PG
Citation: P. Damsbo et al., Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes, DIABET RE C, 45(1), 1999, pp. 31-39
Authors:
van Heiningen, PNM
Hatorp, V
Nielsen, KK
Hansen, KT
van Lier, JJ
van De Merbel, NC
Oosterhuis, B
Jonkman, JHG
Citation: Pnm. Van Heiningen et al., Absorption, metabolism and excretion of a single oral dose of C-14-repaglinide during repaglinide multiple dosing, EUR J CL PH, 55(7), 1999, pp. 521-525
Citation: V. Hatorp et al., Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers, INT J CL PH, 36(12), 1998, pp. 636-641